Piper Sandler lowered the firm’s price target on Day One Biopharmaceuticals to $40 from $45 on account of expected increase in spend with the transition to a commercial-stage company, while keeping an Overweight rating on the shares following FY24 earnings and pipeline update. Tovorafenib continues to track towards a potential April 2024 approval in r/r pLGG. Management reiterated that the review process has proceeded in-line with their expectations and that FDA engagement has been timely and productive, the firm says. The potential confirmatory FIREFLY-2 is also clearly well underway with more than 80 global sites now activated. Altogether, Piper continues to believe that tovorafenib is very well-positioned for a potential upcoming approval and sees Day One as sufficiently capitalized to realize this opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DAWN:
- A New Cause for Concern: Day One Biopharmaceuticals, Inc. Adds a New Regulation Risk
- Day One Biopharmaceuticals Updates Corporate Presentation
- Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
- Capital One says buy these six biotech stocks for 2024
- Capital One reveals top six biotech picks for 2024